Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.83
EPS est.
$-0.82
EPS surprise
-1.59%
1-day move
-1.40%
Scholar Rock's earnings report shows a larger-than-expected loss per share, which likely contributed to the stock's decline of 1.4%. The lack of revenue and guidance may raise concerns among investors about the company's short-term prospects. Overall, the results indicate challenges ahead for Scholar Rock as it navigates its financial landscape.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.83 | $-0.78 | -1.59% |
| Revenue | $0M | $0M | — |
No transcript is on record, and the analysis is based on numerical results only.
Scholar Rock Holding Corporation operates in the biotechnology sector, focusing on developing therapies for serious diseases. With a market cap of $6 billion, the company is important for investors interested in innovative healthcare solutions and advancements in biotechnology.
Last quarter
In Q4-2025, Scholar Rock reported an EPS of $-0.88, slightly missing expectations. The stock saw a modest increase of 1.91% the following day.
EPS beat streak
0Q
EPS beat rate
13%
Avg EPS surprise
-9.48%
Avg 1-day reaction
+2.44%
Analysts expect a continued trend of losses, with an EPS estimate of $-0.78. Investors are particularly focused on any signs of operational progress or product development.
Bull case
If the company can demonstrate significant advancements in its drug pipeline or unexpected revenue streams, it could lead to a positive reassessment of its future.
Bear case
On the other hand, if losses widen or there are delays in product development, it could lead to further declines in stock price.
Key metrics to watch
EPS
$-0.78Earnings per share is a key indicator of profitability and financial health, and investors will be looking for any signs of improvement.
Revenue
$0MWhile no revenue is expected this quarter, any updates on future revenue streams or product launches could be significant.
The print will turn on these.
Q1
Will EPS come in better than the consensus estimate of $-0.78?
A smaller loss than expected could signal operational improvements and boost investor confidence.
Q2
What updates can management provide on product development and future revenue streams?
Any positive news on upcoming therapies or partnerships could significantly impact the stock's outlook.
—
Est. EPS
$-0.76
Est. Rev
$192M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating the potential for operational improvements and pipeline advancements that could lead to better-than-expected results this quarter.
Supporting evidence
The options market indicates a significant move, suggesting that investors anticipate volatility.
Recent insider selling could indicate a lack of confidence in short-term performance, which contrasts with potential long-term growth.
The historical trend of stock reactions suggests that even small improvements can lead to positive stock movements.
Key risk
If the company announces any unexpected progress in its drug pipeline, it could challenge the current consensus.
Pre-commit to what would confirm each case.
This quarter's performance is crucial as it may indicate the company's ability to recover from previous losses and gain traction in the market.
Bull confirmed if
A narrower EPS loss than $-0.78, coupled with positive commentary on product development, would confirm the bull case.
Bear confirmed if
A wider EPS loss than $-0.78 with no updates on product progress would confirm the bear case.
What the market is pricing for the move.
Implied Move
±7.86%
Historical Avg
±6.6%
The options market is pricing in a significant move around the earnings announcement, indicating uncertainty among investors.
Options are pricing ±8.7% while SRRK has averaged ±6.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
50.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Scholar Rock beats EPS expectations, history suggests the stock could rise by around 1.56% on the following day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the market may react cautiously, leading to a muted response as investors await further guidance.
Miss
If the company misses expectations, history suggests a potential decline of about 1.56%, which could raise concerns about its future viability.
The lines on the call that would change the story.